Overweight Clinical Trials in Buenos Aires
18 recruitingBuenos Aires, Argentina
Showing 1–18 of 18 trials
Recruiting
Phase 3
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Diabetes MellitusObesityOverweight
Novo Nordisk A/S630 enrolled73 locationsNCT07533175
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Obesity or Overweight
Hoffmann-La Roche2,000 enrolled28 locationsNCT07351045
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Obesity or OverweightType 2 Diabetes Mellitus
Hoffmann-La Roche1,600 enrolled36 locationsNCT07351058
Recruiting
Phase 3
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Obesity and Overweight
Metsera, a wholly owned subsidiary of Pfizer3,500 enrolled196 locationsNCT07311850
Recruiting
Phase 3
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
ObesityOverweightOverweight and/or Obesity
Pfizer999 enrolled184 locationsNCT07400653
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,980 enrolled173 locationsNCT07321886
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
ObesityOverweight
Eli Lilly and Company600 enrolled35 locationsNCT07357415
Recruiting
Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
ObesityOverweight
Eli Lilly and Company1,217 enrolled53 locationsNCT06143956
Recruiting
Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
HypertensionOverweight or Obesity
Eli Lilly and Company487 enrolled99 locationsNCT06948435
Recruiting
Phase 1Phase 2
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Type 2 Diabetes Mellitus (T2DM)Obese or Overweight Healthy Volunteers
Alnylam Pharmaceuticals144 enrolled20 locationsNCT06845202
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,035 enrolled159 locationsNCT07282600
Recruiting
Phase 3
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
OsteoarthritisOverweight or Obesity
Eli Lilly and Company900 enrolled154 locationsNCT07353931
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
ObesityOverweightSleep Apnea, Obstructive
Eli Lilly and Company800 enrolled123 locationsNCT07369011
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Chronic Low Back Pain (CLBP)ObesityOverweight
Eli Lilly and Company586 enrolled41 locationsNCT07035093
Recruiting
Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
ObesityOverweightType 2 Diabetes
Eli Lilly and Company1,200 enrolled80 locationsNCT06993792
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
ObesityOverweight
Eli Lilly and Company600 enrolled80 locationsNCT06972459
Recruiting
Phase 2
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
ObesityDiabetes Mellitus, Type 2Overweight
Eli Lilly and Company200 enrolled38 locationsNCT07215559
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
ObesityOverweightType 2 Diabetes
Eli Lilly and Company600 enrolled77 locationsNCT06972472